Home NEWS AND MEDIA

NeuExcell Therapeutics Announces Encouraging Data of NXL-004 in Recurrent Malignant Glioma at 2026 ASCO

31 May 2026

Related news

01 / Jul 2026

NeuExcell's NXL-004 Achieves 100% One-Year Survival in High-Dose Cohort for Recurrent Malignant Glioma
Learn more
05 / Dec 2025

Clinical | NeuExcell Therapeutics Reports Encouraging Clinical Results with In Situ Conversion Therapy for Malignant Glioma
Learn more
11 / Jun 2025

NeuExcell Therapeutics Announces First Dosing of NXL-001 in a Patient with Ten Years of Alzheimer's Disease
Learn more